5-HT 2C receptor agonists and the control of appetite

Handbook of Experimental Pharmacology

Volumn 209, Issue , 2012, Pages 349-356

  Halford, Jason C G ^a   Harrold, Joanne A ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Appetite; Behaviour; Food intake; Obesity; Satiety

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; DEXFENFLURAMINE; FENFLURAMINE; FLUOXETINE; LORCASERIN; PLACEBO; SEROTONIN 2C AGONIST; SEROTONIN 2C RECEPTOR; SIBUTRAMINE; ANOREXIGENIC AGENT; SEROTONIN 2 AGONIST;

APPETITE; ARTICLE; CARDIOVASCULAR DISEASE; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; EATING HABIT; FOOD INTAKE; HUMAN; HYPERPHAGIA; NONHUMAN; OBESITY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SATIETY; TREATMENT DURATION; VALVULAR HEART DISEASE; WEIGHT REDUCTION; ANIMAL; DRUG EFFECT; FEEDING BEHAVIOR; METABOLISM; PATHOPHYSIOLOGY; PSYCHOLOGICAL ASPECT; REVIEW; TREATMENT OUTCOME;

ANIMALS; APPETITE DEPRESSANTS; APPETITE REGULATION; FEEDING BEHAVIOR; HUMANS; OBESITY; RECEPTOR, SEROTONIN, 5-HT2C; SEROTONIN 5-HT2 RECEPTOR AGONISTS; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 84856337834     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/978-3-642-24716-3_16     Document Type: Article

References (51)

1. Abeniam L, Moride Y, Brenot F et al1996) Appetite suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med 335:609-616 (Pubitemid 26277950)
2. Arterburn DE, Crane PK, Veenstra DL2004) The efficacy and safety of sibutramine for weight loss: a systematic review. Arch Intern Med 164:994-1003 (Pubitemid 38581520)
3. Bjenning C, Williams J, Whelan K et al2004) Chronic oral administration of APD356 significantly reduces body weight and fat mass in obesity-proneDIO) male and female rats. Int J Obes 28(suppl 1):214
4. Blundell JE1977) Is there a role for serotonin5-hydroxytryptamine) in feeding? Int J Obes 1:15-42
5. Blundell JE, Halford JCG1998) Serotonin and appetite regulation: implications for the treatment of obesity. CNS Drugs 9:473-495 (Pubitemid 28293699)
6. Blundell JE, Hill AJ1990) Sensitivity of the appetite control system in obese subjects to nutritional and serotoninergic challenges. Int J Obes 14:219-233 (Pubitemid 20150407)
7. Blundell JE, Latham CJ1978) Pharmacological manipulation of feeding behaviour: possible influences of serotonin and dopamine on food intake. In: Garattini S, Samanin Reds) Central mechanisms of anorectic drugs. Raven, NY, pp 83-109
8. Blundell JE, Latham CJ1980) Characteristic adjustments to the structure of feeding behaviour following pharmacological treatments: effects of amphetamine and fenfluramine and the antagonism by pimozide and metergoline. Pharmacol Biochem Behav 12:717-722 (Pubitemid 10045717)
9. Blundell JE, McArthur RA1981) Behavioural flux and feeding: continuous monitoring of food intake and food selection, and the video-recording of appetitive and satiety sequences for the analysis of drug action. In: Samanin R, Garattini Seds) Anorectic agents: mechanisms of action and tolerance. Raven, NY, pp 19-43
10. Chapelot D, Mamonier C, Thomas F et al2000) Modalities of the food intake-reducing effect ofsibutramine in humans. Physiol Behav 68:299-308 (Pubitemid 30100696)
11. Clifton PG1994) The neuropharmacology of meal patterning. In: Cooper SJed) Ethology and psychopharmacology. Wiley, Chichester, pp 313-328
12. Cowen PJ, Sargent PA, Williams C et al1995) Hypophagic, endocrine and subjective responses to m-chlorophenylpiperazine in healthy men and women. Hum Psychopharmacol 10:385-391
13. Goodall E, Silverstone T1988) Differential effect of d-fenfluramine and metergoline on food intake in human subjects. Appetite 11:215-288
14. Haddock CK, Poston WSC, Dill PL et al2002) Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials. Int J Obes 26:262-273 (Pubitemid 34151206)
15. Halford JCG, Blundell JE1993) 5-Hydroxytryptaminergic drugs compared on the behavioural sequence associated with satiety. Br J Pharmacol 100:95
16. Halford JCG, Boyland EJ, Cooper SJ et al2010a) The effects of sibutramine on the microstructure of eating behaviour and energy expenditure in obese women. J Psychopharmacol 24:99-109
17. Halford JCG, Boyland EJ, Blundell JE et al2010b) Pharmacological management of human appetite expression: evaluating the effects of novel anti-obesity agents on eating behaviour. Nat Endocrine Rev 6:255-269
18. Halford JCG, Harrold JA, Boyland EJ, Lawton CL, Blundell JE2007) Serotonergic drugs: effects on appetite expression and use for the treatment of obesity. Drugs 67:27-55 (Pubitemid 46105086)
19. Halford JCG, Blundell JE2000) Separate systems for serotonin and leptin in appetite control. Ann Med 32:222-232 (Pubitemid 30237567)
20. Halford JCG, Wanninayake SCD, Blundell JE1998) Behavioural satiety sequenceBSS) for the diagnosis of drug action on food intake. Pharmacol Biochem Behav 61:159-168 (Pubitemid 28458908)
21. Hansen DL, Toubro S, Stock MJ et al1998) Thermogenic effects of sibutramine in humans. Am J Clin Nutr 68:1180-1186 (Pubitemid 28550946)
22. Hayashi A, Sonoda R, Kimura Y et al2004) Antiobesity effect of YM348, a novel 5-HT2C receptor agonist, in Zucker rats. Brain Res 1011:221-227 (Pubitemid 38638688)
23. Heisler LK, Cowley MA, Tecott LH et al2002) Activation of Central Melanocortin pathways by Fenfluramine. Science 297:609-611 (Pubitemid 34815346)
24. Heisler LK, Cowley MA, Kishi T et al2003) Central serotonin and melanocortin pathways regulating energy homeostasis. N Y Acad Sci 994:169-174 (Pubitemid 36793864)
25. Heisler LK, Jobst EE, Sutton GM et al2006) Serotonin reciprocally regulates melanocortin neurons to modulate food intake. Neuron 51:239-249 (Pubitemid 44063615)
26. Hewitt KN, Lee MD, Dourish CT et al2002) Serotonin 2C receptor agonists and the behavioural satiety sequence in mice. Pharmacol Biochem Behav 71:691-700 (Pubitemid 34219219)
27. Higgs S, Cooper AJ, Barnes NM2011) Reversal of sibutramine-induced anorexia with a selective 5-HT2C receptor antagonist. Psychopharmacology 214:941-947
28. Hoyer D, Martin G1997) 5-HT receptor classification and nomenclature: towards a harmonization with the human genome. Neuropharmacology 36:419-428 (Pubitemid 27272086)
29. James WP, Caterson ID, Coutinho W, Finer N, Van Gaal LF, Maggioni AP, Torp-Pedersen C, Sharma AM, Shepherd GM, Rode RA, Renz CL, SCOUT Investigators2010) Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 363:905-917
30. Kennett GA, Curzon G1988a) Evidence that the hypophagia induced by mCPP and TFMPP requires 5-HT1C and 5-HT1B receptors; hypophagia induced by RU-24969 only requires 5- HT1B receptors. Psychopharmacology 96:93-100
31. Kennett GA, Curzon G1988b) Evidence that mCPP may have behavioural effects mediated by central 5-HT1C receptors. Br J Pharmacol 94:137-147
32. Kitchener SJ, Dourish CT1994) An examination of the behavioural specificity of hypophagia induced by 5-HT1B, 5-HT1C and 5-HT2 receptor agonists using the post-prandial sequence in rats. Psychopharmacology 113:368-377
33. Lawton CL, Wales JK, Hill AJ et al1995) Serotoninergic manipulation, meal-induced satiety and eating patterns. Obes Res 3:345-356
34. Martin CK, Redman LM, Zhang J et al2011) Lorcaserin, a 5-HT2C receptor agonist, reduced body weight by decreasing energy intake within influencing energy expenditure. J Clin Endocrinol Metab 96:837-45
35. McGuirk J, Silverstone T1990) The effect of 5-HT re-uptake inhibitor fluoxetine on food intake and body weight in healthy male subjects. Int J Obes 14:361-372 (Pubitemid 20212177)
36. Nonogaki K, Abdullah L, Goulding EH et al2003) Hyperactivity and reduced energy cost of physical activity in serotonin 5-HT2C receptor mutant mice. Diabetes 52:315-320 (Pubitemid 36173184)
37. Padwal R, Li SK, Lau DCW2003) Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials. Int J Obes 27:1437-46 (Pubitemid 38019154)
38. Pijl H, Koppeschaar HPF, Willekens FLA et al1991) Effect of serotonin re-uptake inhibition by fluoxetine on body weight and spontaneous food choice in obesity. Int J Obes 15:237-242
39. Rogers PJ, Blundell JE1979) Effect of anorexic drugs on food intake and the micro-structure of eating in human subjects. Psychopharmacology 66:159-165 (Pubitemid 10180146)
40. Rolls BJ, Shide DJ, Thorward ML et al1998) Sibutramine reduces food intake in non-dieting women with obesity. Obes Res 6:1-11 (Pubitemid 128679638)
41. Sargent PA, Sharpley AL, Williams C et al1997) 5-HT2C receptor activation decreases appetite and body weight in obese subjects. Psychopharmacology 133:309-312 (Pubitemid 27445666)
42. Smith SR, Prosser WA, Donahue DF et al2009) LorcaserinAPD356), a selective 5-HT2C agonist, reducing body weight in obese men and women. Obesity 17:494-500
43. Smith SR, Wiessman NJ, Anderson CM et al2010) Multicenter, placebo-controlled trial for Lorcaserin for weight management. N Engl J Med 363:245-56
44. Tecott LH, Sun LM, Akanna SF et al1995) Eating disorder and epilepsy in mice lacking 5-HT2C serotonin receptors. Nature 374:542-546
45. Vickers SP, Benwell KR, Porter RH et al2000) Comparative effects of continuous infusion of mCPP, Ro 60-0175 and d-fenfluramine on food intake, water intake, body weight and locomotor activity in rats. Br J Pharmacol 130:1305-1314 (Pubitemid 30488594)
46. Vickers SP, Clifton PG, Dourish CT et al1999) Reduced satiating effect of d-fenfluramine in serotonin 5-HT2C receptor mutant mice. Psychopharmacology 143:309-314 (Pubitemid 29204986)
47. Vickers SP, Dourish CT2004) Serotonin receptor ligands and the treatment of obesity. Curr Opin Investig Drugs 5:377-388
48. Vickers SP, Dourish CT, Kennett GA2001) Evidence that hypophagia induced by d-fenfluramine and d-norfenfluramine in the rat is mediated by 5-HT2C receptors. Neuropharmacology 41:200-209 (Pubitemid 32728091)
49. Vickers SP, Easton N, Webster LJ et al2003) Oral administration of the 5-HT2C receptor agonist, mCPP, reduces body weight gain in rats over 28 days as a result of maintained hypophagia. Psychopharmacology 167:274-280 (Pubitemid 36712974)
50. Walsh AE, Smith KA, Oldman AD1994) M-Chlorophenylpiperazine decreases food intake in a test meal. Psychopharmacology 116:120-122 (Pubitemid 24279609)
51. Ward AS, Comer SD, Haney M et al1999) Fluoxetine-maintained obese humans: effect on food intake and body weight. Physiol Behav 66:815-821 (Pubitemid 29281644)